Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 145,033 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Recruiting Phase 2Phase 3 Interventional

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

NCT07226999
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
PF-08634404, Atezolizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
54
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382899
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pegilodecakin, Pembrolizumab
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
74
States / cities
Huntsville, Alabama • Tempe, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

NCT00553332
View directory record Official record
Conditions
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions
selumetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 21, 2026, 6:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NCT03127098
View directory record Official record
Conditions
Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions
ETBX-011, ALT-803
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 21, 2026, 6:34 PM EDT
Active, not recruiting Not applicable Interventional

Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors

NCT06260332
View directory record Official record
Conditions
Breast Cancer
Interventions
Supportive Care (Fitbit)
Behavioral
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 21, 2026, 6:34 PM EDT
Recruiting Early Phase 1 Interventional

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07210632
View directory record Official record
Conditions
Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, High Grade Glioma (III or IV), High Grade Glioma (HGG) of the Brain With BRAF Aberration
Interventions
Nivolumab, Nivolumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

Building Resilience and Appropriate Independence in Young Adults With Autism

NCT03842332
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Life Skills and Resilience Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 26 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation

NCT02163187
View directory record Official record
Conditions
Rectal Cancer, for Bowel Dysfunction Following Surgery for Rectal Cancers
Interventions
Implantation of the InterStimTM, MSK BFI questionnaires, The Low Anterior Resection Score (LARS) questionnaires, The EuroQOL5D questionnaires, The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires
Device · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

NCT01495793
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 4 Interventional

A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents

NCT00348621
View directory record Official record
Conditions
Cataract, Refractive Error, Low Vision
Interventions
Visual impairment intervention program
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
2,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 6:34 PM EDT
Not listed Not applicable Interventional

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

NCT00924014
View directory record Official record
Conditions
Heart Failure
Interventions
Conivaptan, Furosemide, Conivaptan and furosemide
Drug
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2009 · Synced Oct 21, 2026, 6:34 PM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)

NCT07730814
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 36 Months
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

NCT00536016
View directory record Official record
Conditions
Macular Degeneration
Interventions
JSM6427
Drug
Lead sponsor
Jerini Ophthalmic
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Beverly Hills, California • Boston, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 21, 2026, 6:34 PM EDT
Completed No phase listed Observational

Balloon Aortic Valvuloplasty During Surgical Aortic Valve Replacement

NCT00584116
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs

NCT06988306
View directory record Official record
Conditions
Diabetes Mellitus, Gestational Diabetes Mellitus (GDM)
Interventions
GDM Enhanced, Meals
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
18 Years and older · Female only
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
San Luis Obispo, California • Chicago, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Enrolling by invitation Not applicable Interventional

Patient-centered Precision Medicine Lab Result Communication for Older Adults

NCT07391904
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Health Communication, Patient Comprehension
Interventions
Chronic Kidney Disease (CKD) Lab Result Communication Tool
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

NCT00165204
View directory record Official record
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 21, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services

NCT06128304
View directory record Official record
Conditions
HIV, Cervical Cancer
Interventions
Core Implementation strategies, Core+ Enhanced Implementation Strategies
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years to 64 Years · Female only
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional

TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections

NCT06637904
View directory record Official record
Conditions
Sepsis, Infections, Tachycardia, Fever
Interventions
TriVerity Test
Diagnostic Test
Lead sponsor
Inflammatix
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Peoria, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PilAm Go4Health Weight Loss Program to Prevent Heart Disease

NCT02290184
View directory record Official record
Conditions
Type2 Diabetes
Interventions
PilAm Go4Health Weight-loss Program, Active Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

NCT01399684
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 21, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)

NCT00386672
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Reduced energy (lite) OJ fortified with Calcium and Vitamin D, Nutrition Counseling, Reduced energy (lite) OJ without Calcium and Vitamin D
Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 21, 2026, 6:34 PM EDT
Completed No phase listed Observational

Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer

NCT00711672
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Hematology and Oncology Associates of NE Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dunmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 6:34 PM EDT